In the present study, we were the first to construct a reliable prognostic signature based on three hypoxia-driven genes (CFHR3, CHGA, and EGLN3) and confirm its clinical utility in Patients with HCC. This evidence concerns the gene CHGA and hepatocellular carcinoma.